Bovis ISSN 2398-2993

Ceftiofur

Contributor(s): Louise Cox-O’Shea, Vetstream Ltd , Andrea Tarr

Introduction

Name

  • Ceftiofur.

Class of drug

  • 3rd generation parenterally administered beta-lactam antibacterial.

Description

Chemical name

  • (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.

Molecular formula

  • C19H17N5O7S3.

Molecular weight

  • 523.553 g/mol.

Physical properties

  • Sterile powder for reconstitution.
  • Injectable suspension.

Storage requirements

  • Unreconstituted product should be stored in a refrigerator (2 -8°C).
  • Reconstituted solution can be kept for 7 days between +2 and +8°C.
  • Reconstituted solution can be kept for 12 hours when stored below 25°C.
  • Injectable suspension should be stored below 25°C. 
  • Shake suspension well before withdrawing dose. Discard within 28-30 days of withdrawal of first dose (depending upon product). 

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Ceftiofur-sensitive infections.
  • Acute interdigital necrobacillosis (foul in the foot); where Fusobacterium necrophorum Fusobacterium necrophorum & Bacteroides melaninogenicus are involved.
  • Acute respiratory disease (due to Mannheimia haemolytica Mannheimia haemolytica, Pasteurella multocida Pasteurella multocida, Actinobacillus somnus and other pathogens sensitive to Ceeftiofur).
  • Puerperal metritis within 10 days of calving where other antimicrobial treatment has failed.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmacokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

With other drugs

  • There may be an increased risk of nephrotoxicity when used in association with loop diuretics and aminoglycoside antimicrobials.
  • Bacteriostatic antimicrobials may reduce the efficacy of ceftiofur.
  • There may be reduced metabolism of phenylbutazone and phenytoin.
  • There may be reduced barbiturate metabolism and prolongation of phenobarbital anesthesia.

Withdrawal Period

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed Papers

Other sources of information

  • PubChem (2017) Open chemistry database ceftiofur. U.S. National library of medicine, National centre for biotechnology information. PubMed.
  • Yolande Bishop (ed) (2005) The Veterinary Formulary. 6th edn. Published in association with the British Veterinary Association.
  • National office of animal health [online]. NOAH compendium of datasheets. Website: www.noahcompendium.co.uk. Last accessed 15th March 2018.
  • Veterinary medicines directorate [online]. VMD product database. Website: www.vmd.defra.gov.uk. Last accessed 15th March 2018.
  • Plumb’s veterinary drugs [online]. Website: www.plumbsveterinarydrugs.com. Last accessed 15th March 2018.

ADDED